Companies
The technique, used in noninvasive prenatal testing to detect microduplications or microdeletions, could detect copy number alterations in B-cell lymphoma patients.
TCR2 Therapeutics, BMS to Study Gavo-Cel, Opdivo, Yervoy Combos in Mesothelin-Expressing Cancers
The Phase II study will evaluate various combinations of the immunotherapies in patients with NSCLC, ovarian cancer, bile duct cancer, and mesothelioma.
Agencies and drugmakers are struggling to generate consistent standards and regulatory criteria for evaluating autologous cell therapies.
Hummingbird Bioscience, Merck to Study HMBD-002 With Keytruda in Various Solid Tumors
The firms plan to evaluate the anti-VISTA and anti-PD-1 therapies in a clinical trial for TNBC, NSCLC, and other cancers with high VISTA expression.
European Commission Approves Merck's Keytruda-Chemo Combination for Advanced TNBC Patients
The approval makes Merck's PD-1 inhibitor available to European TNBC patients whose tumors express PD-L1 with a combined positive score of at least 10.